Completed PHASE2 INTERVENTIONAL 3-arm NCT00926380

Denosumab, Teriparatide or Both for the Treatment of Postmenopausal Osteoporosis (DATA)

The Denosumab And Teriparatide Administration Study (DATA)

Sponsor: Amgen

Updated 9 times since 2017 Last updated: May 30, 2018 Started: Jun 30, 2009 Primary completion: Dec 31, 2016 Completion: Dec 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Osteoporosis, this trial is completed. The trial is conducted by Amgen and has accumulated 9 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2

▶ Show 4 earlier versions

Jul 2018 — Jan 2021 [monthly]

Completed PHASE2
Jun 2018 — Jul 2018 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Feb 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE2

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen
Massachusetts General Hospital

Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States